Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404924 · ClinicalTrials.gov registry record · Phase 3
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,140
- Enrollment target
NCT00404924: Completed Phase 3 study, sponsored by Genzyme, a Sanofi Company.
NCT00404924 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 1,140 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00404924, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,140 participants
- Enrollment target
Study Summary
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.
Primary Outcome
Overall Survival (OS) is defined as the time from date of randomization until death. Any blinded/unknown patient which have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie, their status must be known at the censored date and should not be lost to follow up or unknown).
Interventions
- OTHER Best Supportive Care
- DRUG ZD6474 (vandetanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,140 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
What the finished NCT00404924 record still lists
NCT00404924 is an interventional study that assigns participants to a tested intervention. Its 1,140 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% higher).
The record links to 0 conditions, and to 2 interventions - of which Best Supportive Care is the first listed.
NCT00404924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00404924 about?
NCT00404924 is a clinical study titled "ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures". This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Ty...
What is the current status of trial NCT00404924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,140 participants. The study started on 2006-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00404924?
The interventions under investigation include: Best Supportive Care (OTHER), ZD6474 (vandetanib) (DRUG).
Who is sponsoring clinical trial NCT00404924?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00404924's enrollment target sits among peer trials
1,140 243rd of 2000 higher than 1,758 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia